Anti-Candida Activity of New Azole Derivatives Alone and in Combination with Fluconazole

详细信息    查看全文

• 作者：Ce Shi ; Chunli Liu ; Jinyan Liu ; Ying Wang ; Jian Li ; Mingjie Xiang
• 关键词：Candida ; Antifungal ; Azole ; Synergistic ; Resistance ; Fluconazole
• 刊名：Mycopathologia
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：180
• 期：3-4
• 页码：203-207
• 全文大小：359 KB
• 参考文献：1.Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29:239鈥?4.CrossRef PubMed
  2.Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol. 2007;45:321鈥?6.CrossRef PubMed
  3.Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;21:133鈥?3.CrossRef
  4.Odds FC, Brown AJP, Gow NAR. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11:272鈥?.CrossRef PubMed
  5.Kothavade RJ, Kura MM, Valand AG, Panthaki MH. Can-dida tropicalis : its prevalence, pathogenicity and increasing resistance to fluconazole. J Med Microbiol. 2010;59:873鈥?0.CrossRef PubMed
  6.Beyda ND, Lewis RE, Garey KW. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother. 2012;46:1086鈥?6.CrossRef PubMed
  7.Chandrasekar P. Management of invasive fungal infections: a role for polyenes. J Antimicrob Chemother. 2011;66:457鈥?5.CrossRef PubMed
  8.Boiani M, Gonzalez M. Imidazole and benzimidazole derivatives as chemotherapeutic agents. Med Chem. 2005;5:409鈥?4.
  9.Dhainaut A, Tizot A, Raimbaud E, Lockhart B, Lestage P, Goldstein S. Synthesis, structure, and neuroprotective properties of novel imidazolyl nitrones. Med Chem. 2000;43:2165鈥?5.CrossRef
  10.Rani N, Sharma A, Gupta GK, Singh R. Imidazoles as potential antifungal agents: a review. Med Chem. 2013;13:1626鈥?5.
  11.Khan ZK, Jain P. Antifungal agents and immunomodulators in systemic mycoses. Indian J Chest Dis Allied Sci. 2000;42:345鈥?6.PubMed
  12.Sud IJ, Chou DL, Feingold DS. Effect of free fatty acids on liposome susceptibility to imidazole antifungals. Antimicrob Agents Chemother. 1979;16:660鈥?.PubMed Central CrossRef PubMed
  13.Mahmoudabadi A, Drucker D. Effect of amphotericin B, nystatin and miconazole on the polar lipids of Candida albicans and Candida dubliniensis. Indian J Pharmacol. 2006;38:423.CrossRef
  14.Bossche HV, Engelen M, Rochette F. Antifungal agents of use in animal health鈥揷hemical, biochemical and pharmacological aspects. J Vet Pharmacol Ther. 2003;26:5鈥?9.CrossRef
  15.Niwano Y, Tabuchi T, Kanai K, Hamaguchi H, Uchida K, Yamaguchi H. Short-term topical therapy of experimental tinea pedis in guinea pigs with lanoconazole, a new imidazole antimycotic聽agent. Antimicrob Agents Chemother. 1995;39:2353鈥?.PubMed Central CrossRef PubMed
  16.Niwano Y, Ohmi T, Seo A, Kodama H, Koga H, Sakai A. Lanoconazole and its related optically active compound NND-502: novel antifungal imidazoles with a ketene dithioacetal structure. Curr Med Chem Anti-Infect Agents. 2003;2:147鈥?0.CrossRef
  17.Jones BM, Geary I, Lee ME, Duerden BI. Comparison of the in vitro activities of fenticonazole, other imidazoles, metronidazole, and tetracycline against organisms associated with bacterial vaginosis and skin infections. Antimicrob Agents Chemother. 1989;33:970鈥?.PubMed Central CrossRef PubMed
  18.Liu CL, Shi C, Mao F, et al. Discovery of new imidazole derivatives containing the 2,4-dienone motif with broad-spectrum antifungal and antibacterial activity. Molecules. 2014;19:15653鈥?2.CrossRef PubMed
  19.Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts鈥攖hird edition: approved standard M27-A3. Wayne: CLSI; 2008.
  20.Zhang J, Liu W, Tan J, Sun Y, Wan Z, Li R. Antifungal activity of geldanamycin alone or in combination with fluconazole against Candida species. Mycopathologia. 2013;175:273鈥?.CrossRef PubMed
  21.Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52:1.CrossRef PubMed
  22.Geogriev VS. Membrane transporters and antifungal drug resistance. Curr Drug Target. 2000;1:261鈥?4.CrossRef
  23.Holland IB, Blight MA. ABC-ATPase, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans. J Mol Biol. 1999;293:381鈥?9.CrossRef PubMed
  24.Sanglard D, Iseher F, Koymans L, et al. Amino acid substitutions in the cytochrome P450 Lanosterol 14alpha demethylase (CYP51A1) from azole-resistance Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother. 1998;42:241鈥?3.PubMed Central CrossRef PubMed
  25.Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Clin Infect Dis. 2002;35:1073鈥?0.CrossRef PubMed
  26.Xiang MJ, Liu JY, Ni PH, et al. Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. FEMS Yeast Res. 2013;13:386鈥?3.CrossRef PubMed
  
• 作者单位：Ce Shi (1) (2)
  Chunli Liu (3)
  Jinyan Liu (2)
  Ying Wang (1)
  Jian Li (3)
  Mingjie Xiang (1) (2)
  
  1. Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China
  2. Radioimmunology and Clinical Laboratory, Luwan Branch, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200020, China
  3. Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai, 200237, China
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Life Sciences
  Microbiology
  Medical Microbiology
  Plant Sciences
  Microbial Ecology
  
• 出版者：Springer Netherlands
• ISSN：1573-0832

文摘

The rate of Candida spp. infection is increasing, and resistance to azole antifungals is becoming increasingly common. Therefore, there is a need for discovery of new antifungal agents and for development of new modes of treatment using existing agents. In this in vitro study, the antifungal activity of two new imidazole derivatives was tested against a set of 20 Candida isolates, which included five different species. Treatment was carried out with the compound alone and in combination with fluconazole. Overall, we found that one of the new compounds, 31, was similar to fluconazole (FLC) in its efficacy against the Candida isolates and that compound 42 was superior to FLC. Furthermore, when combined with FLC, both compounds showed synergistic effects against 17 of the 20 tested isolates. No antagonistic interactions were observed. This study shows that our two new imidazole-derived compounds have good potential as general treatments for Candida infection and as a means to improve the current treatments with FLC. Keywords Candida Antifungal Azole Synergistic Resistance Fluconazole